Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.

Exclusion Criteria

• •History of hypersensitivity to any of the components of the drugs under investigation.
• •Use of ophthalmic medications from any pharmacological group.
• •Use of medications by any other route of administration.
• •In the case of women: being pregnant, breastfeeding, or planning to become pregnant within the study period.
• •Having participated in any clinical research study 30 days prior to inclusion in this study.
• •Having previously participated in this same study.
• •History of any chronic-degenerative disease, including Diabetes Mellitus or Systemic Arterial Hypertension.
• •Diagnosis of glaucoma or ocular hypertension.
• •Known diagnosis of liver or heart disease.
• •Presenting active inflammatory or infectious disease at the time of entry into the study.
• •Presenting unresolved lesions or traumas at the time of entry into the study.
• •Having been subjected to non-ophthalmological surgical procedures in the last 3 months.
• •Being or having an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is an employee of the research site or the sponsor, and who directly participates in this study.
• •Elimination Criteria
• •Withdrawal of their consent to participate in the study (informed consent form).
• •Occurrence of a serious adverse event, whether related or not to the interventions, that in the opinion of the principal investigator (PI) and/or the sponsor, could affect the patient's fitness to safely continue with the study procedures.
• •Non-tolerability or hypersensitivity to any of the compounds used during the tests -(fluorescein, tetracaine).
• •Non-tolerability or hypersensitivity to any of the drugs under investigation.
• •Adherence \< 80% determined by the subject's diary and corroborated by the final weight of the research products (RP) compared to the initial weight.